"natco-pharma"

In a breakthrough for India’s pharmaceutical sector, firms including Hetero, Cipla, Annora, and Natco have won Chinese government bids to supply generic drugs like Dapagliflozin and Olaparib, marking a significant entry into China’s tightly controlled healthcare market

Should the offer be accepted, the company will hold a 35.75 per cent stake in the South Africa firm, valued at R4 billion (USD 226 million), the company stated in a regulatory filing

The pharma company saw its net profit dip 37.75 per cent to Rs 132.4 crore in the December quarter, hit by lower formulations exports

Hyderabad based Natco pharma and its associate Lupin Limited got yet another US FDA approval for manufacture of Bosentan tablets

Hyderabad City-based Natco Pharma said that the Appeals Court in the US has rejected its marketing partner Alvogen’s appeal on Ibrutinib tablets. These are proposed generic equivalents to Imbruvica tablets made Pharmacyclics LLC. It is indicated in the treatment of cancer. Natco and its co-development and marketing partner Alvogen Pine Brook are assessing their option […]

Hyderabad: Hyderabad-based Natco Pharma reported a dip in its net profit for the quarter ended September 30, 2021 to Rs 65.1 crore as against Rs 203.90 crore in the same period last fiscal. The company registered a Rs 415.2 crore consolidated revenue during the quarter under review as against Rs 827.9 crore in the second […]

Hyderabad: A simple pill to treat Covid-19 positive patients! Yes, an anti-viral pill that could be easily prescribed and taken orally by Covid positive patients with a promise of cutting down the risk of hospitalisation and death by at least by half, could hit the Indian markets in the coming months. Multiple research institutions and […]

For the entire 2020-21 fiscal, the company posted a consolidated net profit of Rs 442 crore as compared with Rs 458 crore in 2019-20.

Natco Pharma had recently received approval from the Drug Controller General of India (DCGI) to conduct phase III clinical trials of Molnupiravir

Task Force also discussed with them various alternatives to drugs that are in high demand like Remdesivir

Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE. 

Hyderabad-headquartered comprehensive cancer care provider expects to close Series A funding in the second half of 2021

With this launch, cotton farmers will have a new and powerful tool to manage PBW, Natco Pharma said.

The consolidated total income of the company stood at Rs 386 crore for the quarter under consideration.

During the year, Natco spent Rs 349 crore on capital expenditure, a majority of which was used to enhance capabilities of their manufacturing facilities